Cargando…

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

BACKGROUND: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonanno, Laura, Costa, Carlota, Majem, Margarita, Sanchez, Jose-Javier, Rodriguez, Ignacio, Gimenez-Capitan, Ana, Molina-Vila, Miquel Angel, Vergnenegre, Alain, Massuti, Bartomeu, Favaretto, Adolfo, Rugge, Massimo, Pallares, Cinta, Taron, Miquel, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868003/
https://www.ncbi.nlm.nih.gov/pubmed/27179511
http://dx.doi.org/10.1186/s12885-016-2339-5
_version_ 1782432123384233984
author Bonanno, Laura
Costa, Carlota
Majem, Margarita
Sanchez, Jose-Javier
Rodriguez, Ignacio
Gimenez-Capitan, Ana
Molina-Vila, Miquel Angel
Vergnenegre, Alain
Massuti, Bartomeu
Favaretto, Adolfo
Rugge, Massimo
Pallares, Cinta
Taron, Miquel
Rosell, Rafael
author_facet Bonanno, Laura
Costa, Carlota
Majem, Margarita
Sanchez, Jose-Javier
Rodriguez, Ignacio
Gimenez-Capitan, Ana
Molina-Vila, Miquel Angel
Vergnenegre, Alain
Massuti, Bartomeu
Favaretto, Adolfo
Rugge, Massimo
Pallares, Cinta
Taron, Miquel
Rosell, Rafael
author_sort Bonanno, Laura
collection PubMed
description BACKGROUND: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. METHODS: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. RESULTS: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0–1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004). CONCLUSIONS: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2339-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4868003
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48680032016-05-17 Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer Bonanno, Laura Costa, Carlota Majem, Margarita Sanchez, Jose-Javier Rodriguez, Ignacio Gimenez-Capitan, Ana Molina-Vila, Miquel Angel Vergnenegre, Alain Massuti, Bartomeu Favaretto, Adolfo Rugge, Massimo Pallares, Cinta Taron, Miquel Rosell, Rafael BMC Cancer Research Article BACKGROUND: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. METHODS: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. RESULTS: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0–1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004). CONCLUSIONS: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2339-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-14 /pmc/articles/PMC4868003/ /pubmed/27179511 http://dx.doi.org/10.1186/s12885-016-2339-5 Text en © Bonanno et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bonanno, Laura
Costa, Carlota
Majem, Margarita
Sanchez, Jose-Javier
Rodriguez, Ignacio
Gimenez-Capitan, Ana
Molina-Vila, Miquel Angel
Vergnenegre, Alain
Massuti, Bartomeu
Favaretto, Adolfo
Rugge, Massimo
Pallares, Cinta
Taron, Miquel
Rosell, Rafael
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
title Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
title_full Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
title_fullStr Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
title_full_unstemmed Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
title_short Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
title_sort combinatory effect of brca1 and herc2 expression on outcome in advanced non-small-cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868003/
https://www.ncbi.nlm.nih.gov/pubmed/27179511
http://dx.doi.org/10.1186/s12885-016-2339-5
work_keys_str_mv AT bonannolaura combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT costacarlota combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT majemmargarita combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT sanchezjosejavier combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT rodriguezignacio combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT gimenezcapitanana combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT molinavilamiquelangel combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT vergnenegrealain combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT massutibartomeu combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT favarettoadolfo combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT ruggemassimo combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT pallarescinta combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT taronmiquel combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer
AT rosellrafael combinatoryeffectofbrca1andherc2expressiononoutcomeinadvancednonsmallcelllungcancer